Abstract
Introduction
There has been growing interest on medical therapy for the management of Cushing’s disease (CD), particularly in cases of persistent or recurrent hypercortisolism. Ketoconazole, an inhibitor of adrenal steroidogenesis, is the most widely used drug, whereas cabergoline and pasireotide are the most promising centrally acting agents. The main purpose of this review article is to highlight the options of medical treatment for CD, with a special emphasis on combination therapies, a topic that has only been addressed by a limited number of studies.
Conclusions
According to the results of these studies, combination therapies involving medications with additive or synergistic effects on ACTH and cortisol secretion seem quite attractive as they yield higher probability of longterm control of the hypercortisolism at lower doses, a lower incidence of side-effects, and possibly a lower rate of treatment escapes. Currently, ketoconazole, cabergoline, and pasireotide are the best drugs to be prescribed in combination.
Similar content being viewed by others
References
Colao A, Boscaro M, Ferone D, Casanueva FF (2014) Managing Cushing’s disease: the state of the art. Endocrine 47(1):9–20
Tritos NA, Biller BM (2014) Cushing’s disease. Handb Clin Neurol 124:221–234
Biller BM, Grossman AB, Stewart PM et al (2008) Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 93(7):2454–2462
Sheth SA, Bourne SK, Tritos NA, Swearingen B (2012) Neurosurgical treatment of Cushing disease. Neurosurg Clin N Am 23(4):639–651
Atkinson AB, Kennedy A, Wiggam MI, McCance DR, Sheridan B (2005) Long-term remission rates after pituitary surgery for Cushing’s disease: the need for long-term surveillance. Clin Endocrinol (Oxf) 63(5):549–559
Patil CG, Prevedello DM, Lad SP et al (2008) Late recurrences of Cushing’s disease after initial successful transsphenoidal surgery. J Clin Endocrinol Metab 93(2):358–362
Fleseriu M (2012) Medical management of persistent and recurrent Cushing’s disease. Neurosurg Clin N Am 23(4):653–668
Pashtan I, Oh KS, Loeffler JS (2014) Radiation therapy in the management of pituitary adenomas. Handb Clin Neurol 124:317–324
Oßwald A, Plomer E, Dimopoulou C et al (2014) Favorable long-term outcomes of bilateral adrenalectomy in Cushing’s disease. Eur J Endocrinol 171(2):209–215
Vilar L, Naves LA, Azevedo MF et al (2010) Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing’s disease. Pituitary 13(2):123–129
Feelders RA, Hofland LJ (2013) Medical treatment of Cushing’s disease. J Clin Endocrinol Metab 98(2):425–438
Feelders RA, de Bruin C, Pereira AM et al (2010) Pasireotide alone or with cabergoline and ketoconazole in Cushing’s disease. N Engl J Med 362(2):1846–1848
Fleseriu M, Petersenn S (2013) New avenues in the medical treatment of Cushing’s disease: corticotroph tumor targeted therapy. J Neurooncol 114(1):1–11
Fleseriu M (2014) Recent advances in the medical treatment of Cushing’s disease. F1000prime Rep 6:18
Tritos NA, Biller BM (2012) Advances in medical therapies for Cushing’s syndrome. Discov Med 13(69):171–179
Tritos NA, Biller BM (2014) Medical management of Cushing’s disease. J Neurooncol 117(3):407–414
Trainer PJ (2013) New options for the medical treatment of Cushing’s syndrome. Indian J Endocrinol Metab 17(2):245–248
Cuevas-Ramos D, Fleseriu M (2014) Treatment of Cushing’s disease: a mechanistic update. J Endocrinol 223(2):R19–R39
Castinetti F, Laurence G, Pauline G et al (2014) Ketoconazole in Cushing’s disease: is it worth a try? J Clin Endocrinol Metab 99(5):1623–1630
Juszczak A, Ertorer ME, Grossman A (2013) The therapy of Cushing’s disease in adults and children: an update. Horm Metab Res 45(2):109–117
Lewis JH, Zimmerman HJ, Benson GD, Ishak KG (1984) Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases. Gastroenterology 86(3):503–513
Verhelst JA, Trainer PJ, Howlett TA et al (1991) Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing’s syndrome. Clin Endocrinol (Oxf) 35(2):169–178
Baudry C, Coste J, Bou Khalil R et al (2012) Efficiency and tolerance of mitotane in Cushing’s disease in 76 patients from a single center. Eur J Endocrinol 167(4):473–481
Preda VA, Sen J, Karavitaki N, Grossman AB (2012) Etomidate in the management of hypercortisolaemia in Cushing’s syndrome: a review. Eur J Endocrinol 167(4):137–143
Fleseriu M, Petersenn S (2012) Medical management of Cushing’s disease: what is the future? Pituitary 15(3):330–341
Bertagna X, Pivonello R, Fleseriu M et al (2014) LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing’s disease: results from a multicenter, proof-of-concept study. J Clin Endocrinol Metab 99(4):1375–1383
Fleseriu M, Biller BM, Findling JW, SEISMIC Study Investigators et al (2012) Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing’s syndrome. J Clin Endocrinol Metab 97(6):2039–2049
Carmichael JD, Fleseriu M (2013) Mifepristone: is there a place in the treatment of Cushing’s disease? Endocrine 44(1):20–32
Fleseriu M, Findling JW, Koch CA et al (2014) Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing’s disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone. J Clin Endocrinol Metab 99(10):3718–3727
Gadelha MR, Vieira Neto L (2014) Efficacy of medical treatment in Cushing’s disease: a systematic review. Clin Endocrinol (Oxf) 80(1):1–12
Pecori Giraldi F, Ambrogio AG, Andrioli M et al (2012) Potential role for retinoic acid in patients with Cushing’s disease. J Clin Endocrinol Metab 97(10):3577–3583
Vilar L, Freitas MC, Naves LA et al (2008) Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1,234 patients. J Endocrinol Investig 31(5):436–444
Vilar L, Azevedo MF, Naves LA et al (2011) Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR. Pituitary 14(2):148–156
Vilar L, Czepielewski MA, Naves LA, Rollin GA, Casulari LA, Coelho CE (2007) Substantial shrinkage of adenomas cosecreting growth hormone and prolactin with use of cabergoline therapy. Endocr Pract 13(4):396–402
Chanson P, Salenave S, Kamenicky P (2014) Acromegaly. Handb Clin Neurol 124:197–219
Pivonello R, De Martino MC, Cappabianca P et al (2009) The medical treatment of Cushing’s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 94(1):223–230
Godbout A, Manavela MP, Danilowicz K et al (2010) Cabergoline monotherapy in the long-term treatment of Cushing’s disease. Eur J Endocrinol 163(5):709–716
Lila AR, Gopal RA, Acharya SV et al (2010) Efficacy of cabergoline in uncured (persistent or recurrent) Cushing disease after pituitary surgical treatment with or without radiotherapy. Endocr Pract 16(6):968–976
Güven A, Baltacıoğlu F, Dursun F, Cebeci AN, Kırmızıbekmez H (2013) Remission with cabergoline in adolescent boys with Cushing’s disease. J Clin Res Pediatr Endocrinol 5(3):194–198
Manavela MP, Danilowicz K, Bruno OD (2012) Macrocorticotropinoma shrinkage and control of hypercortisolism under long-term cabergoline therapy: case report. Pituitary 15(Suppl 1):33–36
Casulari LA, Naves LA, Mello PA, Pereira Neto A, Papadia C (2004) Nelson’s syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment. Horm Res 62(6):300–305
Barber TM, Adams E, Wass JA (2014) Nelson syndrome: definition and management. Handb Clin Neurol 124:327–337
Cuevas-Ramos D, Fleseriu M (2014) Somatostatin receptor ligands and resistance to treatment in pituitary adenomas. J Mol Endocrinol 52(3):R223–R240
Ben-Shlomo A, Schimd H, Wawrowsky K (2010) Differential ligand mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy. J Clin Endocrinol Metab 94(11):4342–4350
Neggers SJ, van der Lely AJ (2014) Medical approach to pituitary tumors. Handb Clin Neurol 124:303–316
Murray RD, Kim K, Ren SG et al (2004) The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. J Clin Endocrinol Metab 89(6):3027–3032
Colao A, Petersenn S, Newell-Price J, Pasireotide B2305 Study Group et al (2012) A 12-month phase 3 study of pasireotide in Cushing’s disease. N Engl J Med 366(10):914–924
Boscaro M, Bertherat J, Findling J et al (2014) Extended treatment of Cushing’s disease with pasireotide: results from a 2-year, phase II study. Pituitary 17(4):320–326
Colao A, De Block C, Gaztambide MS et al (2014) Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations. Pituitary 17(2):180–186
Kamenicky P, Droumaguet C, Salenave S et al (2011) Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing’s syndrome. J Clin Endocrinol Metab 96(9):2796–2804
Child DF, Burke CW, Burley DM, Rees LH, Fraser TR (1976) Drug controlled of Cushing’s syndrome. Combined aminoglutethimide and metyrapone therapy. Acta Endocrinol (Cph) 82(2):330–341
Trainer PJ, Besser M (1994) Cushing’s syndrome. Therapy directed at the adrenal glands. Endocrinol Metab Clin N Am 23(3):571–584
Pivonello R, De Leo M, De Martino MC et al (2009) Effectiveness and safety of combined therapy with low dose ketoconazole and cabergoline in patients with Cushing’s disease partially responsive to monotherapy with cabergoline. In: Program of the 11th international pituitary congress, Washington, pp 36–40
Barbot M, Albiger N, Ceccato F et al (2014) Combination therapy for Cushing’s disease: effectiveness of two schedules of treatment. Should we start with cabergoline or ketoconazole? Pituitary 17(2):109–117
Vignati F, Loli P (1996) Additive effect of ketoconazole and octreotide in the treatment of severe adrenocorticotropin dependent hypercortisolism. J Clin Endocrinol Metab 81(8):2885–2890
Van Schaeybroeck S, Van Imschoot S, Cochez P (2002) Ectopic ACTH-syndrome due to a thymic carcinoid tumor. Acta Clin Belg 57(1):23–25
European Medicines Agency (EMA) (2012) European public assessment report. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002052/WC500128058.pdf. verified 10/10/2014
Nieman LK (2013) Update in the medical therapy of Cushing’s disease. Curr Opin Endocrinol Diabetes Obes 20(4):330–334
Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC (2000) Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288(5463):154–157
Di Ieva A, Rotondo F, Syro LV, Cusimano MD, Kovacs K (2014) Aggressive pituitary adenomas–diagnosis and emerging treatments. Nat Rev Endocrinol 10(7):423–435
Dillard TH, Gultekin SH, Delashaw JB et al (2011) Temozolomide for corticotroph pituitary adenomas refractory to standard therapy. Pituitary 14(1):80–91
Bode H, Seiz M, Lammert A et al (2010) SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. Exp Clin Endocrinol Diabetes 118(10):760–763
Zacharia BE, Gulati AP, Bruce JN et al (2014) High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series. Neurosurgery 74(4):E447–E455
Conflict of interest
Marcello Bronstein is a principal investigator of the clinical trial CSOM230G2304 (Pasireotide LAR for Cushing´s disease). The other authors have no conflicts of interest to disclose.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vilar, L., Naves, L.A., Machado, M.C. et al. Medical combination therapies in Cushing’s disease. Pituitary 18, 253–262 (2015). https://doi.org/10.1007/s11102-015-0641-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11102-015-0641-x